reports
NewtekOne, Inc. Reports First Quarter 2024 Financial Results
NewtekOne, Inc. Reports First Quarter 2024 Financial Results Achieves Growth in Loans and Deposits in the First Quarter 2024 First Quarter 2024 Earnings per Share Beats Company’s Previously Issued Forecast; Company Raises Full Year 2024 Earnings per Share Forecast BOCA RATON, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (Nasdaq: NEWT), announced today its financial and operating results for the three months ended March 31, 2024. NewtekOne First Quarter 2024 Financial Highlights Net income was $9.7 million, or $0.38 per ...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and P...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Phase 3 trial results of AXS-12 in narcolepsy announced Topline results of ADVANCE-2 Phase 3 tr...
Corcept Therapeutics Announces First Quarter Financial Results and Pro...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024. Financial Results Revenue of $146.8 million, a 39 percent increase over the same period in 2023Increase in 2024 ...
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Axsome Therapeutics Recognizes May as Mental Health Awareness Month NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living with mental health conditions...
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Corcept Completes Enrollment in Phase 4 CATALYST Trial MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in CATALYST, a Phase 4 trial examining the prevalence of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes; patients with hypercortisolism m...
Corcept Therapeutics to Announce First Quarter Financial Results, Prov...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking Upon registering, each participant will receive a dial-...
NewtekOne, Inc. CEO, Barry Sloane, to Attend the B. Riley Securities 2...
NewtekOne, Inc. CEO, Barry Sloane, to Attend the B. Riley Securities 24th Institutional Investor Conference May 22-23, 2024 BOCA RATON, Fla., April 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NEWT), announced today that NewtekOne’s CEO and President, Barry Sloane, and CFO, M. Scott Price, will attend and hold-one-on-one meetings at the B. Riley Securities 24th Institutional Investor Conference on May 22-23, 2024 at the Beverly Hilton Hotel in Beverly Hills, CA. To schedule a meeting, please contact your B. Riley representative, or Jayne Cavuoto, Director of Investor Relations at NewtekOne, at ...
Corcept Announces Positive Results From Open-Label Portion of Pivotal ...
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacor...
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With ...
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilan...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at th...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced present...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on ...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and provide a business ...
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relac...
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined wi...
NewtekOne, Inc. to Report First Quarter 2024 Financial Results on Mond...
NewtekOne, Inc. to Report First Quarter 2024 Financial Results on Monday, May 6, 2024 After the Market Closes BOCA RATON, Fla., April 04, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT), today announced that it will report its first quarter 2024 financial results after the market closes on Monday, May 6, 2024. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer; M. Scott Price, Chief Financial Officer; and Frank M. DeMaria, Chief Accounting Officer, the following day, Tuesday, May 7, 2024 at 8:30 am ET. Please note, to attend the ...
NewtekOne, Inc. Hires Taylor Quinn as Chief Risk Officer
NewtekOne, Inc. Hires Taylor Quinn as Chief Risk Officer BOCA RATON, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT), announced today that it has hired Mr. Taylor Quinn as Senior Vice President, Chief Risk Officer for NewtekOne and Newtek Bank, N.A., effective today. Mr. Quinn comes to the Company as an established financial services executive with close to 15 years of experience in audit, finance, and risk management with a focus in the banking space. Most recently, Taylor was the Senior Vice President, Chief Audit Executive at Amalgamated Bank where he was resp...
NewtekOne, Inc. Announces Loan Closings for the First Quarter 2024
NewtekOne, Inc. Announces Loan Closings for the First Quarter 2024 Record Loan Approvals Across All Loan Products in First Quarter 2024 Strong Growth in Lending and Deposits in the First Quarter 2024 BOCA RATON, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- (the “Company” or “NewtekOne”) (NASDAQ: NEWT), announced today that its nationally chartered bank subsidiary, Newtek Bank, N.A., closed $207.7 million of SBA 7(a) loans for the three months ended March 31, 2024, which represents a 36.2% increase over $152.5 million of SBA 7(a) loans closed in the first quarter 2023. Newtek Bank and t...
NewtekOne, Inc. Promotes Frank M. DeMaria to Chief Accounting Officer
NewtekOne, Inc. Promotes Frank M. DeMaria to Chief Accounting Officer BOCA RATON, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) has promoted Mr. Frank M. DeMaria to Executive Vice President, Chief Accounting Officer of NewtekOne effective as of March 29, 2024. Mr. DeMaria has been with NewtekOne since May of 2023 as Senior Vice President of Accounting and Finance. Frank brings a career’s worth of experience across many facets of financial holding company accounting and finance to this position. Frank’s prior experience includes being Senior Vice President & Cont...
CORRECTING and REPLACING NewtekOne, Inc. News Release
CORRECTING and REPLACING NewtekOne, Inc. News Release BOCA RATON, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- Today NewtekOne, Inc. (“NewtekOne”) timely filed its annual report on Form 10-K for the period ended December 31, 2023. The purpose of this press release is to update and replace NewtekOne’s press release dated March 5, 2024, which announced NewtekOne’s unaudited fourth quarter and full year 2023 financial results. NewtekOne, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Full Year 2023 Basic Earnings per Share of $1.89 and Diluted Earnings per Share of $1.88 Ne...
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant...
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndr...
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for...
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults. ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomi...
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient ...
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients 77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.